Physician profile
John M Fallucca
NPI 1821208174
$798.94
in general payments reported to CMS, 2019-2025
12 companies · $363 in 2025
The $363 reported for 2025 was less than what a typical Vascular & Interventional Radiology provider received nationally (typical 2025 total: $537).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $150 · 2021: $121 · 2024: $165 · 2025: $363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $527.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $527.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bard Peripheral Vascular, INC. | $150.31 | 2019 | |
| Boston Scientific Corporation | $121.15 | 2021 | |
| Dendreon Pharmaceuticals LLC | $102.89 | 2024-2025 | Provenge |
| Progenics Pharmaceuticals, INC. | $87.75 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $87.30 | 2024-2025 | Keytruda, Welireg, Keytruda Qlex |
| Terumo Medical Corporation | $66.24 | 2025 | Hydropearl, Azur Cx Detachable |
| Sumitomo Pharma America, INC. | $51.75 | 2024-2025 | Gemtesa |
| Janssen Biotech, INC. | $45.54 | 2025 | Erleada, Rybrevant, Carvykti |
| Urogen Pharma, INC. | $24.90 | 2025 | |
| Angiodynamics, INC. | $23.92 | 2024 | Nanoknife |
| Bayer Healthcare Pharmaceuticals INC. | $21.45 | 2024 | |
| Astellas Pharma US INC | $15.74 | 2025 | Xtandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Fallucca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.